Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid for Liver Fat in NAFLD and Type 2 Diabetes
NCT06035874Recruiting
- Sponsor
- Medanta
- Start
- Oct 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bempedoic acid in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Medanta. Primary endpoint: Change in liver fat content at 24 weeks. Started Oct 2023; status: recruiting.
02
Drugs
bempedoic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06035874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035874.